Female CEOs

Editas Medicine

$66.32
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.97 (+3.09%) Today
+$0.56 (+0.85%) As of 9:41 AM UTC after-hours

Why Robinhood?

You can buy or sell EDIT and other stocks, options, and ETFs commission-free!

About EDIT

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA. The listed name for EDIT is Editas Medicine, Inc. Common Stock.

CEO
Cynthia L. Collins
Employees
208
Headquarters
Cambridge, Massachusetts
Founded
2013
Market Cap
4.64B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
4.16M
High Today
$66.64
Low Today
$63.44
Open Price
$64.35
Volume
3.28M
52 Week High
$99.95
52 Week Low
$14.01

Collections

EDIT Earnings

-$0.79
-$0.49
-$0.18
$0.12
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 25, After Hours

You May Also Like

OCSI
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure